Jasper Therapeutics, Inc. (JSPR): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of JSPR were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No JSPR insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
JSPR short interest
Very high short interest. 20.7% of JSPR shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 176%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.87M JSPR shares were sold short, 20.7% of the shares outstanding, up 6.1% from the report before. At the average daily volume of 404,446 shares, buying them all back would take about 17.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.87M | 20.65% | +6% | 404,446 | 17.0 |
| Oct 15, 2026 | 6.47M | 19.46% | +4% | 349,391 | 18.5 |
| Sep 30, 2026 | 6.22M | 18.69% | +7% | 381,578 | 16.3 |
| Sep 15, 2026 | 5.81M | 17.46% | +6% | 353,411 | 16.4 |
| Aug 31, 2026 | 5.49M | 16.51% | +2% | 714,460 | 7.7 |
| Aug 14, 2026 | 5.36M | 16.10% | +24% | 690,501 | 7.8 |
| Jul 31, 2026 | 4.31M | 15.40% | +159% | 4.58M | 1.0 |
| Jul 15, 2026 | 1.66M | 5.94% | -2% | 882,127 | 1.9 |
| Jun 30, 2026 | 1.70M | 6.08% | -13% | 623,080 | 2.7 |
| Jun 15, 2026 | 1.96M | 6.99% | -13% | 957,316 | 2.0 |
| May 29, 2026 | 2.25M | 8.03% | -10% | 236,234 | 9.5 |
| May 15, 2026 | 2.49M | 8.88% | -9% | 242,615 | 10.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Jasper Therapeutics company events
Jasper Therapeutics filed 20 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementJasper Therapeutics, Inc. issued a press release announcing the results of its offer to purchase all of its outstanding warrants to purchase shares of its common stock, par value $0.0001, which were issued and sold as part of an underwritten public offering on September 18, 2025 at a purchase price… Filing
- Nov 4, 2026SharesChanged the rights of its shareholders. Filing
- Oct 15, 2026AnnouncementJasper Therapeutics, Inc. issued a press release announcing that it completed enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). Filing
- Oct 7, 2026AnnouncementJasper Therapeutics, Inc. issued a press release announcing that it has commenced an offer to each holder of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share, that were issued in the Company’s underwritten public offering on September 18, 2025. Filing
- Oct 5, 2026VoteReported shareholder vote results. Filing
- Sep 28, 2026LeadershipHerb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. in order to pursue other professional endeavors. Filing
- Aug 26, 2026Agreement- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 3, 2026VoteReported shareholder vote results. Filing
- Jul 31, 2026AnnouncementAs previously disclosed by Jasper Therapeutics, Inc., a Delaware corporation, on a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on July 16, 2026, in connection with the Company’s acquisition of Kira Pharmaceuticals, a former Cayman Islands exempted… Filing
- Jul 17, 2026LeadershipResignation of Directors In accordance with the Merger Agreement, on July 16, 2026, Vishal Kapoor and Scott Brun, M.D., notified the Board of their resignations, each effective immediately after the Effective Time. Filing
- Jul 16, 2026AnnouncementShared information with investors. Filing
- Jun 9, 2026ListingJasper Therapeutics, Inc. received written notice from The Nasdaq Stock Market LLC indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital… Filing
- Jun 1, 2026AnnouncementShared information with investors. Filing
- May 21, 2026LeadershipChristian Nolet informed the Board of Directors of Jasper Therapeutics, Inc. that he is resigning from the Board and the committees of the Board on which he serves, effective as of the Notice Date. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 30, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementJasper Therapeutics, Inc. issued a press release reporting positive updated clinical data from the Company’s BEACON Phase 1b /2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria, as well as the open-label extension study in CSU and chronic inducible… Filing
- Jan 7, 2026LeadershipThe Board of Directors of Jasper Therapeutics, Inc. determined that, effective January 5, 2026, Ron Martell would cease serving as the Company’s Chief Executive Officer and President. Filing
- Dec 2, 2025AnnouncementJasper Therapeutics, Inc. issued a press release reporting positive preliminary clinical data from the Company’s ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma and the completion of its internal investigation into the anomalous lack of clinical… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Jasper Therapeutics financials
Famous investors that hold JSPR
3 of the 50 well-known investors we track reported holding JSPR in their latest 13F filing. The largest position is Jim Simons's, worth $147K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 252,900 | $147K | 0.0% | +6% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 137,371 | $79.7K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 114,802 | $66.6K | 0.0% | -76% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named JSPR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G | 10.0% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G | 10.0% |
| Nov 13, 2026 | Affinity Asset Advisors, LLC | 13G | 5.6% |
| Nov 13, 2026 | Affinity Asset Advisors, LLC | 13G | 5.6% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G | 6.4% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G | 6.4% |
Questions about Jasper Therapeutics, Inc. (JSPR) stock
Are JSPR insiders buying or selling?
No JSPR insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in JSPR?
As of Oct 30, 2026, 6.87M JSPR shares were sold short, 20.7% of the shares outstanding, up 6.1% from the report before. At the average daily volume of 404,446 shares, buying them all back would take about 17.0 trading days (days to cover). See the history.
Which famous investors hold JSPR?
3 of the 50 well-known investors we track reported JSPR in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $147K. See all holders.
Executive pay
Jasper Therapeutics's chief executive was paid a total of $2.5M for the year ended Dec 31, 2025, down 22% from $3.2M the year before. In the last 12 months, Jasper Therapeutics's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.